Bayer Advances Radiology Development Portfolio and Fosters Innovation in AI

BayerBayer moves ahead with the advancement of its comprehensive Radiology portfolio with progress on the development pipeline of new contrast agents as well as further partnerships in its digital business. The company announced today the presentation of new early clinical data for gadoquatrane, Bayer’s novel macrocyclic gadolinium-based compound currently in Phase II development, at the Radiological Society of North America (RSNA) Annual Meeting. The 2022 RSNA will take place from November 27 to December 1 in Chicago, USA.

In addition, Bayer announced three collaboration agreements for its digital platform Calantic™ Digital Solutions as well as an AI accelerator program, reflecting the company's commitment to driving innovations that benefit patients and their physicians, including leveraging the vast potential of artificial intelligence (AI).

Fostering innovation in Radiology AI

On the occasion of RSNA 2022, Bayer also announced that it will partner with app developers Quantib, ClariPi, and EXINI Diagnostics to strategically expand the offering on its medical imaging platform CalanticTM Digital Solutions. The platform, which was launched recently, delivers access to applications, including those enabled by AI, for medical imaging. With these new collaboration agreements, Bayer is broadening the already available options for thoracic and neurological diseases on the platform by including tools which aim to aid in breast and prostate imaging. With cancer and cardiovascular diseases on the rise, the demand for medical imaging to detect diseases, guide treatment decisions, and aid in therapy planning is growing. AI comes with the value proposition to support diagnosis and increase the throughput of medical imaging examinations.

In addition, Bayer has recently launched CalanticTM SPARK, a new accelerator program for medical imaging app developers to further foster innovation in radiology AI. The program will initially focus on North America and Europe and is planned to be expanded to other regions including Asia-Pacific. Bayer offers a targeted program to accelerate market readiness for early- and late-stage projects and offerings, providing advice spanning medical, regulatory, reimbursement expertise, and market access. Tapping the thriving start-up ecosystem of AI in medical imaging, Calantic SPARK provides program participants with a potential pathway towards commercialization and distribution through Calantic Digital Solutions. Details about Calantic SPARK will be presented at Bayer's booth as well as the AI Showcase Theatre at the RSNA.

About Radiology at Bayer

Everyone deserves clear answers about their health, starting with an early and accurate diagnosis. As a true life science company with a heritage of over 100 years in radiology, Bayer is committed to providing excellence, from innovative products to high-quality services. Bayer has a leading portfolio of contrast media for computed tomography (CT), X-ray, and magnetic resonance imaging (MRI), devices for their precise administration, informatics solutions to support efficient and optimized patient care, as well as acknowledged educational programs, that generated sales of 1.8 billion euros in 2021. In line with the company’s ambition to outperform the radiology market’s average annual growth of 5 percent by 2030, Bayer is strongly committed to research and development, which includes leveraging artificial intelligence and driving innovation in medical imaging. Each of these offerings provides effective tools to support radiologists in their mission to deliver treatment-critical answers and a clear direction - from diagnosis to care.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros.

Most Popular Now

Open Call HORIZON-JU-IHI-2022-03-05: Dig…

Mental health disorders represent an area of severe unmet public health need. This has been further negatively impacted by the COVID-19 pandemic, with a substantial increase in the number and...

The Future of Medicine is Data

At the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new...

Brain Area Necessary for Fluid Intellige…

A team led by UCL and UCLH researchers have mapped the parts of the brain that support our ability to solve problems without prior experience - otherwise known as fluid...

Study Surveys Landscape of Apps Built on…

A study led by Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, is among the first to survey the current landscape of FHIR® apps, providing a snapshot of how...

New Computer Program 'Learns' to Identif…

Genetic mutations cause hundreds of unsolved and untreatable disorders. Among them, DNA mutations in a small percentage of cells, called mosaic mutations, are extremely difficult to detect because they exist...

Applications Open for SpinLab Accelerato…

The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the...

Allscripts Announces Corporate Name Chan…

Allscripts Healthcare Solutions, Inc. announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand...

Bayer to Accelerate Drug Discovery with …

Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run...

220M€ Investment in Testing and Experime…

To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI. Together...

Artificial Nerve Cells - Almost Like Bio…

Researchers at Linköping University (LiU), Sweden, have created an artificial organic neuron that closely mimics the characteristics of biological nerve cells. This artificial neuron can stimulate natural nerves, making it...

AI Tool Developed to Predict Risk of Lun…

Lung cancer is the leading cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is recommended to screen people between 50 and...

For Shared Decision-Making, Telemedicine…

Telemedicine may be just as effective as in-person visits when it comes to shared decision-making and communication for patients undergoing a first-time surgery consultation, according to a study published as...